<DOC>
	<DOCNO>NCT02009605</DOCNO>
	<brief_summary>This study design evaluate efficacy icotinib routine dose previously treat non/light-smoking patient advance squamous cell lung cancer .</brief_summary>
	<brief_title>Icotinib Previously Treated Non/Light-smoking Patients With Advanced Squamous Cell Lung Cancer</brief_title>
	<detailed_description>This study design evaluate efficacy icotinib routine dose previously treat non/light-smoking patient advance squamous cell lung cancer . An objective response ( OR ) define patient best overall response either complete response ( CR ) partial response ( PR ) accord Response Evaluation Criteria Solid Tumors , confirm least 28 day follow date initial response .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>Histologically cytologically confirm metastatic recurrent squamous cell lung cancer primary lesion and/or lymph node , stage IIIB IV patient nonsmoking lightsmoking history . Failure least 1 , 2 , prior chemotherapy regimen advance disease ( either due progressive disease toxicity ) . Have measurable disease , define least one lesion accurately measure least one dimension ( long diameter record ) &gt; = 20 mm conventional technique &gt; = 10 mm spiral CT scan . Be &gt; = 18 year age . Expected survival period 12 week ; ECOG PS 02 . Adequate organ system function define within protocol . Patients history CNS metastases cord compression allow definitively treat clinically stable . Consent compliance research plan followup process , able carry oral therapy ; Provision write informed consent . In woman childbearing age , must start treatment within 7 day urine pregnancy test result negative , lactation period , reproductive age men woman prior entry study , research process 90 day stop agree use reliable method contraception ; Weight loss = &lt; 10 % past 6 month . Adequate tumor tissue detection molecular biomarkers . Patients previously receive treatment EGFRTKIs . Concomitant treatment experimental drug investigation antitumor therapy ; Symptomatic CNS metastases newly diagnose CNS metastases yet definitively treat radiation and/or surgery . Known severe hypersensitivity icotinib excipients product . Presence uncontrolled pleural effusion or/and peritoneal effusion ; Evidence significant clinical disorder laboratory find make undesirable subject participate study . Past current history neoplasm ( entry diagnosis ) past 5 year , exception treat basal cell carcinoma carcinoma situ cervix , cancer cure local therapy alone . Women lactating.or positive pregnancy test .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>icotinib , SCC</keyword>
</DOC>